TCR² Therapeutics Inc.
(NASDAQ GS: TCRR)
Rigrodsky Law, P.A. is investigating TCR² Therapeutics Inc. (“TCR²”) regarding possible breaches of fiduciary duties and other violations of law related to TCR²’s agreement to be acquired by Adaptimmune Therapeutics plc.